About Xias Bio
Xias Bio is a company based in United States founded in 2020. Xias Bio has raised $5.23 million across 2 funding rounds from investors including IndieBio, Happiness Capital and SOSV. Xias Bio offers products and services including LiteProteins, Resilite, ElastiLite, LamiLite, and Keralite. Xias Bio operates in a competitive market with competitors including Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xias Bio Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.23 M (USD)
in 2 rounds
-
Latest Funding Round
$4.98 M (USD), Seed
Sep 04, 2024
-
Investors
IndieBio
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xias Bio
Xias Bio offers a comprehensive portfolio of products and services, including LiteProteins, Resilite, ElastiLite, LamiLite, and Keralite.
Platform for creating sustainable multi-function protein alternatives.
Multi-function protein for cosmetics and biotech applications.
High-performance protein for enhanced product innovations.
Sustainable protein for personal care and biotech uses.
Engineered protein for manufacturing and applications.
Multi-function protein for various industry needs.
Sustainable alternative for biotech and cosmetics.
Optimized protein for performance in multiple sectors.
Protein for innovative product development.
Tailored proteins for specific biotech requirements.
Funding Insights of Xias Bio
Xias Bio has successfully raised a total of $5.23M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.98 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Xias Bio
Xias Bio has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include IndieBio, Happiness Capital and SOSV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are accelerated through IndieBio's focused programs.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Xias Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xias Bio
Investment portfolio details for Xias Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xias Bio
Detailed financials for Xias Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xias Bio Comparisons
Peer comparison for Xias Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xias Bio
Xias Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Lentivirus-based gene and cell therapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
Detailed competitors of Xias Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xias Bio
Complete news archive for Xias Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xias Bio
Xias Bio was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Xias Bio is headquartered in United States.
Xias Bio is a funded company, having raised a total of $5.23M across 2 funding rounds to date.
Xias Bio was founded in 2020 in the United States as a developer of recombinant proteins within the biotechnology sector. Non-immunogenic natural motifs are altered by the company to create enhanced delivery platforms. These materials are applied in areas including cell culture, drug delivery, and cosmeceuticals. Operations focus on producing functional proteins for research and industrial uses.
Xias Bio's top competitors include Phase Genomics, Genenta Science and Genedit.
Xias Bio offers LiteProteins, Resilite, ElastiLite, LamiLite, and 6 more products and services.
Xias Bio has 6 investors. Key investors include IndieBio, Happiness Capital, SOSV, Good Startup, and CPT Capital.